News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
Presentation ACC 2024 Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC) Presenter: Rasha K. Al-Lamee April 08, 2024
News Conference News ACC 2023 Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA Yael L. Maxwell March 09, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2023 On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET Caitlin E. Cox March 04, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses Michael O'Riordan April 06, 2022
News Conference News ACC 2022 Better Angina Relief With Complete PCI in STEMI and MVD L.A. McKeown April 02, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2021 Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM L.A. McKeown May 16, 2021
News Conference News ACC 2020 ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up Shelley Wood March 30, 2020
News Conference News ACC 2020 Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA Shelley Wood March 29, 2020
News Conference News ACC 2019 Time and Money: PCI Public Reporting Requirements Take Their Toll Michael O'Riordan March 26, 2019
News Conference News ACC 2019 High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI Michael O'Riordan March 21, 2019